Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 57.12% | $2.06B | -30.04% | 0.00% |
NTLA | 56.42% | $836.43M | -69.14% | 0.00% |
BEAM | 54.62% | $1.73B | -27.49% | 0.00% |
RGNX | 54.60% | $433.39M | -46.03% | 0.00% |
IMNM | 53.06% | $696.10M | -44.44% | 0.00% |
YMAB | 51.71% | $174.80M | -67.43% | 0.00% |
RCKT | 50.38% | $724.54M | -71.26% | 0.00% |
COGT | 49.46% | $543.09M | -36.14% | 0.00% |
BNT | 49.11% | $11.98B | +33.22% | 0.00% |
BN | 49.06% | $98.39B | +33.78% | 0.55% |
RXRX | 48.79% | $1.73B | -55.31% | 0.00% |
IONS | 48.53% | $5.25B | -12.31% | 0.00% |
CRNX | 48.52% | $2.92B | -39.88% | 0.00% |
VSH | 47.80% | $2.05B | -36.62% | 2.67% |
CRSP | 47.46% | $3.14B | -34.78% | 0.00% |
NCZ | 47.45% | - | - | 5.92% |
NDAQ | 47.20% | $46.66B | +30.61% | 1.18% |
KYMR | 47.20% | $1.95B | -15.67% | 0.00% |
RARE | 46.91% | $3.29B | -18.24% | 0.00% |
OCUL | 46.74% | $1.14B | +14.35% | 0.00% |
Double maintains 2 strategies that include ARWR - Arrowhead Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSMW | -0.03% | $102.62M | 0.18% |
AGZ | 0.05% | $607.46M | 0.2% |
IBTL | -0.07% | $367.56M | 0.07% |
FTSM | 0.12% | $6.54B | 0.45% |
USFR | 0.13% | $18.91B | 0.15% |
TDTT | -0.13% | $2.47B | 0.18% |
XBIL | 0.14% | $782.40M | 0.15% |
STIP | 0.32% | $11.88B | 0.03% |
GOVT | 0.34% | $27.25B | 0.05% |
CMBS | 0.35% | $427.55M | 0.25% |
IBTK | -0.36% | $431.59M | 0.07% |
SCHR | -0.36% | $10.53B | 0.03% |
SHV | 0.37% | $20.94B | 0.15% |
BUXX | 0.40% | $284.43M | 0.25% |
TFLO | -0.63% | $7.06B | 0.15% |
VGIT | -0.68% | $31.33B | 0.04% |
IBTM | -0.77% | $313.33M | 0.07% |
FLGV | 0.84% | $976.63M | 0.09% |
FXY | -0.88% | $838.61M | 0.4% |
SPTI | -0.90% | $8.70B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -42.97% | $140.49M | 0.59% |
VIXY | -40.38% | $109.64M | 0.85% |
BTAL | -37.49% | $361.41M | 1.43% |
IVOL | -14.96% | $353.94M | 1.02% |
FTSD | -13.81% | $212.46M | 0.25% |
TPMN | -11.52% | $31.54M | 0.65% |
CLIP | -11.05% | $1.50B | 0.07% |
XHLF | -9.87% | $1.46B | 0.03% |
TBLL | -9.59% | $2.46B | 0.08% |
SHYM | -9.10% | $322.93M | 0.35% |
XONE | -8.95% | $603.24M | 0.03% |
UTWO | -8.35% | $387.71M | 0.15% |
GBIL | -8.20% | $6.17B | 0.12% |
UNG | -7.88% | $371.83M | 1.06% |
SPTS | -7.71% | $5.76B | 0.03% |
USDU | -6.94% | $173.44M | 0.5% |
TBIL | -6.79% | $5.76B | 0.15% |
BILS | -6.60% | $3.96B | 0.1356% |
SCHO | -5.70% | $10.87B | 0.03% |
ULST | -5.52% | $637.77M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 67.73% | $40.65M | 0.5% |
XBI | 64.87% | $4.85B | 0.35% |
IBB | 61.58% | $5.22B | 0.45% |
ARKG | 56.72% | $944.78M | 0.75% |
PINK | 55.68% | $131.52M | 0.5% |
PBE | 55.12% | $214.12M | 0.58% |
FBT | 54.87% | $994.71M | 0.56% |
BBH | 54.77% | $327.42M | 0.35% |
IWC | 54.44% | $766.88M | 0.6% |
IWO | 53.86% | $11.36B | 0.24% |
KJUL | 53.72% | $113.35M | 0.79% |
KJAN | 53.37% | $305.13M | 0.79% |
IWM | 53.32% | $63.95B | 0.19% |
VTWO | 53.28% | $12.07B | 0.07% |
QQQJ | 53.24% | $610.08M | 0.15% |
ISCG | 53.13% | $645.00M | 0.06% |
SCHA | 52.90% | $16.91B | 0.04% |
NUSC | 52.89% | $1.14B | 0.31% |
ESML | 52.82% | $1.81B | 0.17% |
TMSL | 52.82% | $748.48M | 0.55% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -10.76% | $21.28M | -72.45% | 0.00% |
CBOE | -8.52% | $22.95B | +20.67% | 1.12% |
CYCN | -8.36% | $9.37M | +2.39% | 0.00% |
VHC | -7.87% | $34.69M | +74.89% | 0.00% |
CCRN | -7.05% | $457.33M | -5.30% | 0.00% |
FMTO | -7.02% | $45.74M | -99.96% | 0.00% |
KR | -5.71% | $44.68B | +24.17% | 1.89% |
ED | -4.82% | $36.75B | +5.26% | 3.28% |
K | -4.54% | $28.49B | +32.17% | 2.77% |
VSA | -4.08% | $7.04M | -49.24% | 0.00% |
EXC | -4.07% | $43.84B | +12.45% | 3.59% |
STG | -3.96% | $27.05M | -37.35% | 0.00% |
NEUE | -3.39% | $62.05M | +13.56% | 0.00% |
CME | -2.59% | $98.74B | +28.80% | 3.84% |
AQB | -1.07% | $2.96M | -61.58% | 0.00% |
AWK | -1.00% | $27.37B | +4.54% | 2.22% |
DG | -0.98% | $20.45B | -36.56% | 2.55% |
OCFT | -0.85% | $265.28M | +232.26% | 0.00% |
ESGR | -0.37% | $4.98B | +8.17% | 0.00% |
CNC | -0.30% | $29.89B | -22.14% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AEP | -0.16% | $54.28B | +9.80% | 3.61% |
CNC | -0.30% | $29.89B | -22.14% | 0.00% |
LTM | 0.32% | $11.01B | -96.75% | 2.75% |
ESGR | -0.37% | $4.98B | +8.17% | 0.00% |
GFI | 0.43% | $18.61B | +31.67% | 2.75% |
OCFT | -0.85% | $265.28M | +232.26% | 0.00% |
DG | -0.98% | $20.45B | -36.56% | 2.55% |
AWK | -1.00% | $27.37B | +4.54% | 2.22% |
HEES | 1.00% | $3.52B | +99.54% | 1.15% |
AQB | -1.07% | $2.96M | -61.58% | 0.00% |
ZCMD | 1.43% | $32.45M | -11.38% | 0.00% |
CHD | 1.54% | $23.29B | -11.36% | 1.23% |
SRRK | 1.57% | $2.92B | +115.29% | 0.00% |
MSEX | 1.69% | $1.02B | -1.01% | 2.34% |
JWN | 1.98% | $4.10B | +15.75% | 3.10% |
MSIF | 1.99% | $715.25M | +28.42% | 7.05% |
NOC | 2.16% | $67.51B | -0.35% | 1.76% |
PPC | 2.26% | $11.21B | +41.54% | 0.00% |
DRD | 2.29% | $1.23B | +63.69% | 2.01% |
PRA | 2.30% | $1.19B | +58.17% | 0.00% |
Finnhub
RAGE Silencing via Inhaled Epithelium Targeted siRNA Mitigates Neutrophilic ...
Finnhub
RAGE Haplodeficient Mice are Partially Protected From Allergen Induced Type 2 Inflammation Timothy N. Perkins, PhD1*, David I Kasahara, PhD2, Taylor Reed2, Holly Hamilton, PhD2,...
Yahoo
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline of RNA interference (RNAi) therapies utilizing the company’s TRiM™ platform. The TRiM platform allows for targeting of RNAi therapeutics to seven different cell types, including liver, lung, skeletal muscle, CNS, adipose, ocular, and cardiomyocyte.
Yahoo
Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating regulatory and market uncertainties.
SeekingAlpha
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ETCompany ParticipantsVincent Anzalone - Vice President...
Yahoo
PASADENA, Calif., May 12, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results.
Current Value
$15.371 Year Return
Current Value
$15.371 Year Return